Coombes R C, Easty G C, Detre S I, Hillyard C J, Stevens U, Girgis S I, Galante L S, Heywood L, Macintyre I, Neville A M
Br Med J. 1975 Oct 25;4(5990):197-9. doi: 10.1136/bmj.4.5990.197.
Twenty-three out of 28 patients with metastatic breast carcinoma and one out of 13 patients with localised disease had raised levels of plasma immunoreactive calcitonin. Monolayer cultures of breast carcinomas maintained for up to 10 weeks released immunoreactive calcitonin, and a primary breast carcinoma passaged in "nude" mice for over a year contained material immunologically and chromatographically resembling the monomeric form of human calcitonin. These studies indicate that breast carcinomas can produce calcitonin and that plasma calcitonin measurements may be useful in staging patients with breast carcinomas.
28例转移性乳腺癌患者中有23例,13例局限性疾病患者中有1例血浆免疫反应性降钙素水平升高。乳腺癌单层培养物维持长达10周可释放免疫反应性降钙素,一株在“裸”鼠体内传代一年以上的原发性乳腺癌含有在免疫学和色谱学上与人降钙素单体形式相似的物质。这些研究表明乳腺癌可产生降钙素,血浆降钙素检测可能有助于乳腺癌患者的分期。